Literature DB >> 15980685

Expression of chemokine receptors CCR5 and CXCR4 on CD4+ T cells and plasma chemokine levels during treatment of active tuberculosis in HIV-1-coinfected patients.

Dawit Wolday1, Belete Tegbaru, Afework Kassu, Tsehaynesh Messele, Roel Coutinho, Debbie van Baarle, Frank Miedema.   

Abstract

The pathogenesis of persistently elevated plasma HIV viremia in patients coinfected with tuberculosis (TB) during anti-TB treatment in Africans remains unknown. We examined the expression of chemokine receptors CCR5 and CXCR4 on CD4+ T cells and plasma chemokine levels of macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, regulated on activation normal T expressed and secreted (RANTES), and stromal cell-derived factor (SDF)-1alpha among TB patients with HIV coinfection during the first 2 months of anti-TB treatment. During treatment of TB, the plasma HIV-1 load and CD4+ T-cell count remained unchanged. Levels of CCR5 and CXCR4 expression on CD4+ T cells as well as plasma levels of chemokines remained persistently elevated during anti-TB treatment. Persistently elevated plasma HIV viremia also paralleled persistently elevated expressions of activated CCR5+ or CXCR4+ CD4+ T cells. These results suggest that increased expression of CCR5 and CXCR4 on an activated CD4+ T-cell population coupled with persistently elevated chemokines may provide a suitable condition for continuous replication of HIV associated with TB coinfection. This, in turn, may contribute, at least in part, to the observed persistently elevated plasma HIV viremia in coinfected patients despite anti-TB treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980685     DOI: 10.1097/01.qai.0000163027.47147.2e

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  8 in total

Review 1.  Inflammation and HIV Transmission in Sub-Saharan Africa.

Authors:  Rupert Kaul; Jessica Prodger; Vineet Joag; Brett Shannon; Sergey Yegorov; Ronald Galiwango; Lyle McKinnon
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

Review 2.  Immunology of Mycobacterium tuberculosis Infections.

Authors:  Jonathan Kevin Sia; Jyothi Rengarajan
Journal:  Microbiol Spectr       Date:  2019-07

3.  Dual-targeted anti-TB/anti-HIV heterodimers.

Authors:  Liudmila Alexandrova; Sonia Zicari; Elena Matyugina; Anastasia Khandazhinskaya; Tatiana Smirnova; Sofya Andreevskaya; Larisa Chernousova; Christophe Vanpouille; Sergei Kochetkov; Leonid Margolis
Journal:  Antiviral Res       Date:  2017-07-22       Impact factor: 5.970

Review 4.  Immunological biomarkers of tuberculosis.

Authors:  Gerhard Walzl; Katharina Ronacher; Willem Hanekom; Thomas J Scriba; Alimuddin Zumla
Journal:  Nat Rev Immunol       Date:  2011-04-08       Impact factor: 53.106

5.  Relationship between chemokine receptor expression, chemokine levels and HIV-1 replication in the lungs of persons exposed to Mycobacterium tuberculosis.

Authors:  Barbara Kalsdorf; Keira H Skolimowska; Thomas J Scriba; Rod Dawson; Keertan Dheda; Kathryn Wood; Jessica Hofmeister; Willem A Hanekom; Christoph Lange; Robert J Wilkinson
Journal:  Eur J Immunol       Date:  2012-12-13       Impact factor: 5.532

Review 6.  Mollicutes/HIV Coinfection and the Development of AIDS: Still Far from a Definitive Response.

Authors:  Caio Mauricio Mendes de Cordova; Caroline Galgowski; Leonardo Lange
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-06-16       Impact factor: 2.471

7.  Tuberculosis and Its "Troubled Relationship" With Other Diseases.

Authors:  Maria João Correia; Marta Maio Herculano; Joana Duarte; Filipa Brás Monteiro; Eduarda Carmo
Journal:  Cureus       Date:  2022-07-01

8.  Plasma Biomarkers Can Predict Treatment Response in Tuberculosis Patients: A Prospective Observational Study.

Authors:  Meng-Rui Lee; Chia-Jung Tsai; Wei-Jie Wang; Tzu-Yi Chuang; Chih-Mann Yang; Lih-Yu Chang; Ching-Kai Lin; Jann-Yuan Wang; Chin-Chong Shu; Li-Na Lee; Chong-Jen Yu
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.